ALAS2

Across TCGA pan-cancer cohorts, ALAS2 RNA is linked to patient survival in 19 of 34 cancer types, making it the most broadly survival-associated ALAS2 data layer compared with 5 for mutation status.

The strongest signal is observed in mesothelioma (MESO), where higher ALAS2 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated ALAS2 expression acts as an unfavorable survival marker, although some lineages such as KIRC and LIHC show a favorable association.

MESO, KIRC, and COAD are the cancer types where ALAS2 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	OS	Median	All	0.392	0.682	<.001	73	view →
KIRC	DFS	Median	IV	0.759	0.485	.002	31	view →
COAD	DFS	Median	All	0.411	0.591	.004	29	view →
LUAD	DFS	Quartile	III,IV	0.378	0.718	.025	20	view →
BLCA	DFS	Median	All	0.562	0.664	.011	16	view →
LIHC	DFS	Quartile	III,IV	0.542	0.154	.001	15	view →
KIRP	OS	Quartile	All	0.722	0.936	.025	12	view →
PCPG	DFS	Median	All	0.976	0.665	.002	12	view →
DLBC	DFS	Quartile	All	0.227	0.882	.010	10	view →
UCEC	DFS	Tertile	All	0.545	0.798	.015	10	view →
SKCM	OS	Median	All	0.386	0.290	.014	9	view →
ACC	DFS	Quartile	IV	0.048	0.507	.004	9	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 19 lineages.

ALAS2–MESO (OS)

Open the MESO breakdown →